JP2023526283A5 - - Google Patents
Info
- Publication number
- JP2023526283A5 JP2023526283A5 JP2022569035A JP2022569035A JP2023526283A5 JP 2023526283 A5 JP2023526283 A5 JP 2023526283A5 JP 2022569035 A JP2022569035 A JP 2022569035A JP 2022569035 A JP2022569035 A JP 2022569035A JP 2023526283 A5 JP2023526283 A5 JP 2023526283A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- unsubstituted
- substituted
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026033895A JP2026083268A (ja) | 2020-05-15 | 2026-03-04 | 単独療法及び併用療法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063025490P | 2020-05-15 | 2020-05-15 | |
| US63/025,490 | 2020-05-15 | ||
| US202063040832P | 2020-06-18 | 2020-06-18 | |
| US63/040,832 | 2020-06-18 | ||
| US202063089419P | 2020-10-08 | 2020-10-08 | |
| US63/089,419 | 2020-10-08 | ||
| US202163160325P | 2021-03-12 | 2021-03-12 | |
| US63/160,325 | 2021-03-12 | ||
| US202163161828P | 2021-03-16 | 2021-03-16 | |
| US63/161,828 | 2021-03-16 | ||
| PCT/US2021/032094 WO2021231653A1 (en) | 2020-05-15 | 2021-05-12 | Mono- and combination therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026033895A Division JP2026083268A (ja) | 2020-05-15 | 2026-03-04 | 単独療法及び併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526283A JP2023526283A (ja) | 2023-06-21 |
| JP2023526283A5 true JP2023526283A5 (cg-RX-API-DMAC7.html) | 2024-05-17 |
Family
ID=78525230
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022569035A Pending JP2023526283A (ja) | 2020-05-15 | 2021-05-12 | 単独療法及び併用療法 |
| JP2026033895A Pending JP2026083268A (ja) | 2020-05-15 | 2026-03-04 | 単独療法及び併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026033895A Pending JP2026083268A (ja) | 2020-05-15 | 2026-03-04 | 単独療法及び併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230210854A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4153594A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023526283A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230010729A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115867551A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021271844A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022023254A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3182270A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL298201A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022014131A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI906299B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021231653A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021097139A1 (en) | 2019-11-15 | 2021-05-20 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| KR20230038523A (ko) | 2020-07-09 | 2023-03-20 | 리커리엄 아이피 홀딩스, 엘엘씨 | Wee1 억제제의 염 및 형태 |
| JP2024546584A (ja) * | 2021-12-15 | 2024-12-26 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ |
| WO2023147297A2 (en) * | 2022-01-25 | 2023-08-03 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| WO2024102650A1 (en) * | 2022-11-08 | 2024-05-16 | Zeno Management, Inc. | Intermittent dosing regimen for azenosertib in treating cancer |
| TW202502354A (zh) * | 2023-06-02 | 2025-01-16 | 美商薩諾管理公司 | 同源重組修復缺陷(hrd)作為預測性生物標記以便使用wee1抑制劑治療癌症 |
| WO2025193930A1 (en) * | 2024-03-14 | 2025-09-18 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
| WO2025226653A1 (en) * | 2024-04-23 | 2025-10-30 | Zeno Management, Inc. | Wee1 inhibitor combination therapy dosing regimen |
| WO2025245463A1 (en) * | 2024-05-23 | 2025-11-27 | Merck Patent Gmbh | Combination therapies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3043945A1 (en) * | 2016-11-16 | 2018-05-24 | Sui Xiong Cai | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6h)-ones |
| MX2020001235A (es) * | 2017-08-01 | 2020-07-20 | Recurium Ip Holdings Llc | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. |
| CN109422754A (zh) * | 2017-08-24 | 2019-03-05 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| BR112020018286A2 (pt) * | 2018-03-09 | 2020-12-29 | Recurium Ip Holdings, Llc | 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas |
| CN112142748B (zh) * | 2019-06-28 | 2023-07-04 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
-
2021
- 2021-05-12 CA CA3182270A patent/CA3182270A1/en active Pending
- 2021-05-12 WO PCT/US2021/032094 patent/WO2021231653A1/en not_active Ceased
- 2021-05-12 EP EP21803601.0A patent/EP4153594A4/en active Pending
- 2021-05-12 US US17/998,561 patent/US20230210854A1/en active Pending
- 2021-05-12 IL IL298201A patent/IL298201A/en unknown
- 2021-05-12 AU AU2021271844A patent/AU2021271844A1/en active Pending
- 2021-05-12 CN CN202180043458.3A patent/CN115867551A/zh active Pending
- 2021-05-12 MX MX2022014131A patent/MX2022014131A/es unknown
- 2021-05-12 JP JP2022569035A patent/JP2023526283A/ja active Pending
- 2021-05-12 BR BR112022023254A patent/BR112022023254A2/pt unknown
- 2021-05-12 KR KR1020227043881A patent/KR20230010729A/ko active Pending
- 2021-05-14 TW TW110117495A patent/TWI906299B/zh active
-
2026
- 2026-03-04 JP JP2026033895A patent/JP2026083268A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sørensen et al. | Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | |
| RU2757373C2 (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| JP2020525427A5 (cg-RX-API-DMAC7.html) | ||
| JP2021102627A5 (cg-RX-API-DMAC7.html) | ||
| JP2024516997A5 (cg-RX-API-DMAC7.html) | ||
| ES2426938T3 (es) | Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para tratar cánceres humanos | |
| RU2010117635A (ru) | Комбинированная химиотерапия | |
| JP2021510376A5 (cg-RX-API-DMAC7.html) | ||
| JP2023508332A5 (cg-RX-API-DMAC7.html) | ||
| JP2012523435A5 (cg-RX-API-DMAC7.html) | ||
| JP2023508328A5 (cg-RX-API-DMAC7.html) | ||
| JP2013542241A5 (cg-RX-API-DMAC7.html) | ||
| JP2018525358A5 (cg-RX-API-DMAC7.html) | ||
| JP2024147816A (ja) | がん治療における免疫モジュレーションのための組合せ | |
| JP2022521818A5 (cg-RX-API-DMAC7.html) | ||
| JP2021522197A5 (cg-RX-API-DMAC7.html) | ||
| JP2025503971A5 (cg-RX-API-DMAC7.html) | ||
| US20190240210A1 (en) | Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor | |
| JP2023507797A5 (cg-RX-API-DMAC7.html) | ||
| AU2019271151A1 (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| JP2026506429A (ja) | Mta協同的prmt5阻害薬を使用した癌治療 | |
| JP2022533211A (ja) | 小細胞肺がんの併用療法用キノリン誘導体 | |
| Mir-Bonafé et al. | Adverse hair reactions to new targeted therapies for cancer | |
| AU2023375870A1 (en) | Intermittent dosing regimen for azenosertib in treating cancer | |
| IL278721B1 (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating adenoid cystic carcinoma |